One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to Tesamorelin in México. US research-market identity with a separate FDA-licensed medicine record.

Current source route

Tesamorelin in México

Direct answer / México

Can you buy Tesamorelin in México?

US research-market identity with a separate FDA-licensed medicine record

This record resolves seller-labelled 10 mg tesamorelin research listings. EGRIFTA WR is a separate FDA-licensed prescription product with a specific application, 11.6 mg presentation, indication, label, and regulated supply chain. The research listings do not inherit that approval.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check MéxicoResearch price board
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordUS research-market identity with a separate FDA-licensed medicine record

What Tesamorelin resolves to

This record resolves seller-labelled 10 mg tesamorelin research listings. EGRIFTA WR is a separate FDA-licensed prescription product with a specific application, 11.6 mg presentation, indication, label, and regulated supply chain. The research listings do not inherit that approval.

Evidence lane
Research price board
Current record
4 of 5 rows in stock
Checked
Jul 23, 2026
EgriftaTH9507
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail